间充质干细胞衍生的细胞外囊泡用于人类疾病。

Extracellular vesicles and circulating nucleic acids Pub Date : 2024-02-06 eCollection Date: 2024-01-01 DOI:10.20517/evcna.2023.47
Xiaofang Zhang, Xiaofang Che, Sibo Zhang, Runze Wang, Mo Li, Yi Jin, Tianlu Wang, Yingqiu Song
{"title":"间充质干细胞衍生的细胞外囊泡用于人类疾病。","authors":"Xiaofang Zhang, Xiaofang Che, Sibo Zhang, Runze Wang, Mo Li, Yi Jin, Tianlu Wang, Yingqiu Song","doi":"10.20517/evcna.2023.47","DOIUrl":null,"url":null,"abstract":"<p><p>Stem cell therapy is a novel approach for treating various severe and intractable diseases, including autoimmune disorders, organ transplants, tumors, and neurodegenerative diseases. Nevertheless, the extensive utilization of stem cells is constrained by potential tumorigenicity, challenges in precise differentiation, rejection concerns, and ethical considerations. Extracellular vesicles possess the ability to carry diverse bioactive factors from stem cells and deliver them to specific target cells or tissues. Moreover, they offer the advantage of low immunogenicity. Consequently, they have the potential to facilitate the therapeutic potential of stem cells, mitigating the risks associated with direct stem cell application. Therefore, the use of stem cell extracellular vesicles in clinical diseases has received increasing attention. This review summarizes advances in the use of extracellular vesicles from mesenchymal stem cells (MSC). MSC extracellular vesicles are used in the treatment of inflammatory diseases such as rheumatoid arthritis, liver injury, COVID-19, and allergies; in the repair of tissue damage in heart disease, kidney injury, and osteoarthritic diseases; as a carrier in the treatment of tumors; and as a regenerative agent in neurodegenerative disorders such as Alzheimer's and Parkinson's.</p>","PeriodicalId":520322,"journal":{"name":"Extracellular vesicles and circulating nucleic acids","volume":"5 1","pages":"64-82"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11648454/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mesenchymal stem cell-derived extracellular vesicles for human diseases.\",\"authors\":\"Xiaofang Zhang, Xiaofang Che, Sibo Zhang, Runze Wang, Mo Li, Yi Jin, Tianlu Wang, Yingqiu Song\",\"doi\":\"10.20517/evcna.2023.47\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Stem cell therapy is a novel approach for treating various severe and intractable diseases, including autoimmune disorders, organ transplants, tumors, and neurodegenerative diseases. Nevertheless, the extensive utilization of stem cells is constrained by potential tumorigenicity, challenges in precise differentiation, rejection concerns, and ethical considerations. Extracellular vesicles possess the ability to carry diverse bioactive factors from stem cells and deliver them to specific target cells or tissues. Moreover, they offer the advantage of low immunogenicity. Consequently, they have the potential to facilitate the therapeutic potential of stem cells, mitigating the risks associated with direct stem cell application. Therefore, the use of stem cell extracellular vesicles in clinical diseases has received increasing attention. This review summarizes advances in the use of extracellular vesicles from mesenchymal stem cells (MSC). MSC extracellular vesicles are used in the treatment of inflammatory diseases such as rheumatoid arthritis, liver injury, COVID-19, and allergies; in the repair of tissue damage in heart disease, kidney injury, and osteoarthritic diseases; as a carrier in the treatment of tumors; and as a regenerative agent in neurodegenerative disorders such as Alzheimer's and Parkinson's.</p>\",\"PeriodicalId\":520322,\"journal\":{\"name\":\"Extracellular vesicles and circulating nucleic acids\",\"volume\":\"5 1\",\"pages\":\"64-82\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11648454/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Extracellular vesicles and circulating nucleic acids\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20517/evcna.2023.47\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Extracellular vesicles and circulating nucleic acids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/evcna.2023.47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

干细胞治疗是一种治疗各种严重和难治性疾病的新方法,包括自身免疫性疾病、器官移植、肿瘤和神经退行性疾病。然而,干细胞的广泛应用受到潜在的致瘤性、精确分化的挑战、排斥问题和伦理考虑的限制。细胞外囊泡具有从干细胞中携带多种生物活性因子并将其运送到特定靶细胞或组织的能力。此外,它们具有低免疫原性的优势。因此,它们有可能促进干细胞的治疗潜力,减轻与直接干细胞应用相关的风险。因此,干细胞细胞外囊泡在临床疾病中的应用越来越受到重视。本文综述了间充质干细胞(MSC)细胞外囊泡的应用进展。MSC细胞外囊泡用于治疗炎性疾病,如类风湿关节炎、肝损伤、COVID-19和过敏;在心脏疾病、肾损伤、骨关节炎等疾病的组织损伤修复中;作为肿瘤治疗的载体;作为神经退行性疾病的再生剂,如阿尔茨海默氏症和帕金森症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mesenchymal stem cell-derived extracellular vesicles for human diseases.

Stem cell therapy is a novel approach for treating various severe and intractable diseases, including autoimmune disorders, organ transplants, tumors, and neurodegenerative diseases. Nevertheless, the extensive utilization of stem cells is constrained by potential tumorigenicity, challenges in precise differentiation, rejection concerns, and ethical considerations. Extracellular vesicles possess the ability to carry diverse bioactive factors from stem cells and deliver them to specific target cells or tissues. Moreover, they offer the advantage of low immunogenicity. Consequently, they have the potential to facilitate the therapeutic potential of stem cells, mitigating the risks associated with direct stem cell application. Therefore, the use of stem cell extracellular vesicles in clinical diseases has received increasing attention. This review summarizes advances in the use of extracellular vesicles from mesenchymal stem cells (MSC). MSC extracellular vesicles are used in the treatment of inflammatory diseases such as rheumatoid arthritis, liver injury, COVID-19, and allergies; in the repair of tissue damage in heart disease, kidney injury, and osteoarthritic diseases; as a carrier in the treatment of tumors; and as a regenerative agent in neurodegenerative disorders such as Alzheimer's and Parkinson's.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信